Login
Companies $COYA
$2.96 -$0.04 (1.33%) After hours
Coya Therapeutics, Inc. logo

Coya Therapeutics, Inc.

coyatherapeutics.com

What Do They Do?

Develops therapies that aim to restore regulatory T-cell function, including biologic combinations, for people with neurodegenerative, autoimmune and metabolic diseases.

How Do They Make Money?

Dr. Reddy’s pays Coya under a development and license agreement through upfront license fees, regulatory or commercial milestone payments, and royalties on licensed-product sales. Coya also earns collaboration revenue for research and development services as that work progresses.

FY2025 revenue

Who Are Their Customers?

Dr. Reddy’s works with Coya under a development and license agreement for COYA 302; the arrangement also covers Coya’s research and development services.

Do Revenues Turn Into Profits?

No. It lost $21.2M in FY2025.

Operating income, FY2025
−284% of revenue
▼ −31% (Loss) vs FY2024 (−$17.2M, −485%)
Net income, FY2025
−267% of revenue
▼ −43% (Loss) vs FY2024 (−$14.9M, −419%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −93%
vs $3.6M in Q3 FY2025
Net income
▼ −402% (Loss)
vs −$2.1M in Q3 FY2025
  • Mar 29, 2026 Executive Chairman leaves his role and the board Mark H. Pavao was appointed as an independent director to fill the resulting board vacancy.

From parallel programs to a clinical focus The older report described advancing multiple therapeutic approaches and candidates in parallel. The latest report centers clinical work on its biologic combination for ALS and FTD, while seeking outside support for another candidate and continuing early exosome research.

Who Do They Compete With?

Competes with Ionis Pharmaceuticals, Neurizon Therapeutics, Alchemab Therapeutics, Athira Pharma, NeuroSense Therapeutics, Amylyx Pharmaceuticals, Medicinova, Clene Nanomedicine, Amgen, Nektar Therapeutics, Merck, Xencor, Cue Biopharma, Moderna, ILTOO Pharma, Abata Therapeutics, Sonoma Biotherapeutics, Sangamo Therapeutics, TRex Bio, and Mozart Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support